Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027

New name, plans to domicile in Switzerland reflect maturation of oncology player 

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo

Plus: BeiGene adds to commercial leadership, hiring Pfizer veteran Matt Shaulis, and updates from Wells Fargo, Flagship, Alume, Cytek, Aetion and 180 Life Sciences

IRA’s restructuring of cost-sharing in the catastrophic phase could force plans to restrict utilization

Plus: Medivation vet Hung now chair of T-Therapeutics and updates from Voyager and Eyenuk

March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris

Plus: Pfizer’s, Genmab’s Tivdak gets priority review for full approval and more from Astellas, Cumulus, Pfizer and Innovent

Fears that it would be expanded could chill investment in commercializing academic research, biotech industry says

Plus: Obesity play Carmot seeking NASDAQ IPO and updates from AZ, Astellas, Merck and Lilly